Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05287204
Other study ID # 202002328
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date November 29, 2021
Est. completion date December 30, 2024

Study information

Verified date March 2024
Source University of Iowa
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to determine whether patients with acute kidney injury requiring renal replacement therapy have a higher incidence of muscle wasting than controls and whether the course of recovery is longer compared to controls.


Description:

Acute kidney injury (AKI), the abrupt loss of kidney function, is a common complication that affects more than half of all intensive care unit (ICU) admissions, and it is associated with substantially higher rates of morbidity and mortality in both the short- and the long-term. This is especially true in patients with AKI requiring renal replacement therapy (AKI-RRT), also known as dialysis. An understudied mechanism by which AKI-RRT may contribute to poor clinical outcomes, both in the hospital and after discharge, is through its impact on muscle mass and muscle function. AKI of any severity is known to alter tissue utilization of amino acids, and preliminary data suggest that RRT in the ICU may exacerbate muscle dysfunction through the removal of large quantities of amino acids from the patient's plasma. This study will determine whether patients with AKI-RRT have greater lean muscle loss over 1 week than historical critically ill controls, whether patients with AKI-RRT have diminished recovery of muscle mass and function at 1-3 months following discharge compared to controls, and whether changes in plasma levels of amino acids during hospitalization correlate with loss of muscle function or lack of recovery.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date December 30, 2024
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - >18 years old - AKI requiring CRRT, with enrollment within 48 hours of CRRT initiation Exclusion Criteria: - ICU admission for >7 days - RRT of any kind at any time prior to ICU admission - Chronic kidney disease (CKD) with estimated glomerular filtration rate <20 mL/min/1.73 m2 as calculated by the 2021 CKD-EPI equation - underlying muscle disorders or muscle atrophy such as quadriplegia or hemiplegia, stroke with residual motor deficits, end-stage liver disease, active alcohol use disorder, active malignancy (other than non-melanoma skin cancer) within 1 year, burns, or other baseline neuromuscular disease - pregnancy - concomitant use of other extracorporeal support devices such as ventricular assist devices or extracorporeal membrane oxygenation - anticipated inability to engage in weight-bearing testing after discharge (e.g., trauma or orthopedic surgery) - subjects will be ineligible for outpatient testing if they remain on RRT in the week prior to the research appointment

Study Design


Intervention

Diagnostic Test:
Musculoskeletal ultrasound
Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
Assessments of muscle strength and physical function
A battery of tests of physical function and muscle strength (see outcomes section for details).
Metabolomics
Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent

Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico
United States University of Iowa Iowa City Iowa
United States University of Kentucky Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
University of Iowa

Country where clinical trial is conducted

United States, 

References & Publications (5)

Mayer KP, Dhar S, Cassity E, Denham A, England J, Morris PE, Dupont-Versteegden EE. Interrater Reliability of Muscle Ultrasonography Image Acquisition by Physical Therapists in Patients Who Have or Who Survived Critical Illness. Phys Ther. 2020 Aug 31;100(9):1701-1711. doi: 10.1093/ptj/pzaa068. — View Citation

Mayer KP, Ortiz-Soriano VM, Kalantar A, Lambert J, Morris PE, Neyra JA. Acute kidney injury contributes to worse physical and quality of life outcomes in survivors of critical illness. BMC Nephrol. 2022 Apr 7;23(1):137. doi: 10.1186/s12882-022-02749-z. — View Citation

Mayer KP, Thompson Bastin ML, Montgomery-Yates AA, Pastva AM, Dupont-Versteegden EE, Parry SM, Morris PE. Acute skeletal muscle wasting and dysfunction predict physical disability at hospital discharge in patients with critical illness. Crit Care. 2020 Nov 4;24(1):637. doi: 10.1186/s13054-020-03355-x. — View Citation

Mayer KP, Welle MM, Evans CG, Greenhill BG, Montgomery-Yates AA, Dupont-Versteegden EE, Morris PE, Parry SM. Muscle Power is Related to Physical Function in Patients Surviving Acute Respiratory Failure: A Prospective Observational Study. Am J Med Sci. 2021 Mar;361(3):310-318. doi: 10.1016/j.amjms.2020.09.018. Epub 2020 Oct 3. — View Citation

Teixeira JP, Mayer KP, Griffin BR, George N, Jenkins N, Pal CA, Gonzalez-Seguel F, Neyra JA. Intensive Care Unit-Acquired Weakness in Patients With Acute Kidney Injury: A Contemporary Review. Am J Kidney Dis. 2023 Mar;81(3):336-351. doi: 10.1053/j.ajkd.2022.08.028. Epub 2022 Nov 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary ICU Stage: rectus femoris (RF) cross-sectional area (CSA) RF CSA as assessed by musculoskeletal ultrasound (MSKUS) will be measured at day 0 (study enrollment within 48 hours of CRRT initiation), at day 3, and at day 7 (or at ICU discharge if before day 7). 7 days
Primary ICU Stage: RF muscle thickness (mT) RF mT as assessed by MSKUS will be measured at day 0 (study enrollment within 48 hours of CRRT initiation), at day 3, and at day 7 (or at ICU discharge if before day 7). 7 days
Primary ICU Stage: RF echo intensity (EI) RF EI as assessed by MSKUS will be measured at day 0 (study enrollment within 48 hours of CRRT initiation), at day 3, and at day 7 (or at ICU discharge if before day 7). 7 days
Primary RF CSA at discharge RF CSA as assessed by MSKUS will be measured at hospital discharge. 1 month
Primary RF mT at discharge RF mT as assessed by MSKUS will be measured at hospital discharge. 1 month
Primary RF EI at discharge RF EI as assessed by MSKUS will be measured at hospital discharge. 1 month
Primary RF CSA at post-discharge outpatient visit RF CSA as assessed by MSKUS will be measured at outpatient follow-up visit. 1-3 months
Primary RF mT at post-discharge outpatient visit RF mT as assessed by MSKUS will be measured at outpatient follow-up visit. 1-3 months
Primary RF EI at post-discharge outpatient visit RF mT as assessed by MSKUS will be measured at outpatient follow-up visit. 1-3 months
Primary ICU Stage: ICU Mobility Scale The ICU Mobility Scale is an 11-point scale ranging from 0-10 which involves scoring a patient's maximum level of mobility in the prior 24-hour period. The ICU Mobility Scale will be performed at the same 3 time points as the MSKUS assessments. 7 days
Primary Muscle Strength - Medical Research Council Sum-score (MRC-ss) at discharge MRC-ss is a measure of global peripheral muscle strength that is the current clinical standard for diagnosing ICU-acquired weakness. Muscle strength is assessed by physical exam and rated on an ordinal scale (0-5) at six bilateral muscle groups: shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors. 1 month
Primary Muscle Strength - MRC-ss at post-discharge outpatient visit MRC-ss is a measure of global peripheral muscle strength that is the current clinical standard for diagnosing ICU-acquired weakness. Muscle strength is assessed by physical exam and rated on an ordinal scale (0-5) at six bilateral muscle groups: shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors. 1-3 months
Primary Muscle Strength - knee extension by hand-held dynamometry (HHD) at hospital discharge Maximal isometric knee extensor muscle strength as measured by HHD. 1 month
Primary Muscle Strength - knee extension by HHD at post-discharge outpatient visit Maximal isometric knee extensor muscle strength as measured by HHD. 1-3 months
Primary Muscle Strength - Grip Strength at hospital discharge Maximal isometric grip strength as measured by hand-grip dynamometry (HGD) 1 month
Primary Muscle Strength - Grip Strength at post-discharge outpatient visit Maximal isometric grip strength as measured by HGD 1-3 months
Primary Physical Function - Short Physical Performance Battery (SPPB) at discharge SPPB is a performance-based composite test with a total of 12 points including components of balance (side-by-side stand, semi-tandem stand, and full-tandem stand), chair-to-stand test, and 4-meter habitual gait speed used to assess physical function and physical frailty. 1 month
Primary Physical Function - SPPB at post-discharge outpatient visit SPPB is a performance-based composite test with a total of 12 points including components of balance (side-by-side stand, semi-tandem stand, and full-tandem stand), chair-to-stand test, and 4-meter habitual gait speed used to assess physical function and physical frailty. 1-3 months
Primary TUG Test at post-discharge outpatient visit The Timed Up and Go (TUG) test assesses the time (in seconds) for a subject to stand on command from a seated position, walk 3 meters, turn around, walk back to the chair, and sit down, thereby assessing mobility, physical function, and fall risk. 1-3 months
Primary Physical Function - 6-minute walk test (6MWT) at post-discharge outpatient visit The 6MWT assesses the distance a subject can walk in six minutes, providing a global representation of physical function and cardiopulmonary endurance. 1-3 months
Primary Quality of Life testing using EuroQol Group 5-dimension 5-level (EQ-5D-5L) questionnaire at post-discharge outpatient visit The EQ-5D-5L is a standardized measure of health status developed by the Euro-Qol Group to provide an assessment of health for clinical and economic appraisal. 1-3 months
Primary Physical Function - Clinical Frailty Scale (CFS) at post-discharge outpatient visit CFS is a widely adopted judgement-based tool to screen for frailty and to broadly stratify degrees of fitness and frailty. 1-3 months
Primary Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Questionnaire at post-discharge outpatient visit The FACIT-F scale is a 13-item measure that assesses self-reported fatigue and its impact upon daily activities and function. 1-3 months
Primary 36-Item Short Form Health Survey Physical Function Scale (SF-36) at post-discharge outpatient visit The SF-36 is a 36-item patient-reported survey of health commonly used to evaluate adult patients which contains 8 domains, including a physical function scale based on 10 of the 36 items which has been shown to have high reliability. 1-3 months
Primary Return to driving Yes / No outcome assessed at the outpatient follow-up visit 1-3 months
Primary Return to work or hobby Yes / No outcome assessed at the outpatient follow-up visit 1-3 months
Primary Hospital Readmission Yes / No outcome assessed at the outpatient follow-up visit 1-3 months
Primary Emergency Department Visit Yes / No outcome assessed at the outpatient follow-up visit 1-3 months
Secondary ICU Stage: Changes in Plasma Metabolome Plasma samples will be obtained at day 0 (study enrollment within 48 hours of CRRT initiation), at day 3, and at day 7 (or at ICU discharge if before day 7) and metabolomic analysis will be performed to determine if changes in the plasma metabolome with CRRT initiation correlate with parameters of muscle wasting and/or trajectory of recovery of muscle weakness. 7 days
Secondary ICU Stage: Changes in CRRT Effluent Metabolome CRRT effluent samples will be obtained at day 0 (study enrollment within 48 hours of CRRT initiation), at day 3, and at day 7 (or at ICU discharge if before day 7) and metabolomic analysis will be performed to determine if changes in the effluent metabolome with CRRT initiation correlate with parameters of muscle wasting and/or trajectory of recovery of muscle weakness. 7 days
See also
  Status Clinical Trial Phase
Recruiting NCT05538351 - A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT05805709 - A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT05897840 - Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients N/A
Recruiting NCT04986137 - Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Not yet recruiting NCT06064305 - Transcriptional and Proteomic Analysis of Acute Kidney Injury
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Completed NCT06000098 - Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
Not yet recruiting NCT05548725 - Relation Between Acute Kidney Injury and Mineral Bone Disease
Completed NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A